Diagnosis and prognosis of myocardial infarction on a plasmonic chip.
Wei XuLin WangHongjie DaiXu-Ming SunLin HuangHaiyang SuXunbin WeiChia-Chun ChenJiatao LouHongjie DaiKun QianPublished in: Nature communications (2020)
Cardiovascular diseases lead to 31.5% of deaths globally, and particularly myocardial infarction (MI) results in 7.4 million deaths per year. Diagnosis of MI and monitoring for prognostic use are critical for clinical management and biomedical research, which require advanced tools with accuracy and speed. Herein, we developed a plasmonic gold nano-island (pGold) chip assay for diagnosis and monitoring of MI. On-chip microarray analysis of serum biomarkers (e.g., cardiac troponin I) afforded up to 130-fold enhancement of near-infrared fluorescence for ultra-sensitive and quantitative detection within controlled periods, using 10 μL of serum only. The pGold chip assay achieved MI diagnostic sensitivity of 100% and specificity of 95.54%, superior to the standard chemiluminescence immunoassay in cardiovascular clinics. Further, we monitored biomarker concentrations regarding percutaneous coronary intervention for prognostic purpose. Our work demonstrated a designed approach using plasmonic materials for enhanced diagnosis and monitoring for prognostic use towards point-of-care testing.
Keyphrases
- atrial fibrillation
- high throughput
- percutaneous coronary intervention
- heart failure
- single molecule
- circulating tumor cells
- energy transfer
- cardiovascular disease
- label free
- acute myocardial infarction
- high resolution
- left ventricular
- primary care
- st elevation myocardial infarction
- type diabetes
- single cell
- cardiovascular risk factors
- molecularly imprinted
- coronary artery bypass
- simultaneous determination
- liquid chromatography